Massive Bio

US-based Massive Bio is a patient recruitment platform provider that helps patients diagnosed with cancer to find clinical trial operators and sponsors that are in the process of testing and developing treatments for cancer. The company’s platform utilizes AI to match potential patients with its network of pharmaceutical companies across the world. The company’s platform covers therapeutics being developed for over 30 types of cancers and provides additional services such as clinical decision support, personalized analysis of patient history to suggest treatments, clinical coordination, remote patient monitoring, and educational content. The company additionally has developed two ChatGPT-powered AI platforms: AskFiona AI and DrArturo AI, which provide information for patients looking to join clinical trials and for patients that have been enrolled in clinical trials, respectively.

In June 2024, Massive Bio announced the launch of its "Drug Utilization Optimizer (DUO)". The DUO platform is developed to restructure how pharmaceutical commercial teams communicate with physicians and collect data.

The company operates on a B2B2C basis, charging pharmaceutical companies a subscription rate to list their clinical trials on the platform and help identify potential patients for trials. The company is based in the US but has operations across the globe.

Key customers and partnerships

As of June 2024, the company claimed to have helped over 100,000 120,000 patients across 25 countries find the right trial to participate in from its network of over 14,000 clinical trials registered for pre-screening. MassiveBio also noted that it had 80+ global partners and had sponsored 100 clinical trials.

In March 2023, the company partnered with oncology-related developer NeoGenomics to accelerate the development of cancer therapeutics. Through the partnership, NeoGenomics will identify potential patients based on biomarkers, after which Massive Bio will obtain patient consent, carry out additional required patient screenings, and enroll patients.

In June 2023, the company partnered with oncology-related pharmaceutical developer The Oncology Institute (TOI) to support TOI with evaluating the eligibility of patients for the company’s clinical trial portfolio. Through the partnership, TOI would use Massive Bio’s algorithms and diagnostic information to identify patients for its clinical trials.

In July 2023, Massive Bio partnered with healthcare technology provider CureMatch to advance cancer treatment through advanced genomics, AI, and clinical trial accessibility. Through the partnership, the companies would collaborate to provide oncologists and their patients with access to personalized treatments, relevant clinical trials, and reports indicating the most effective therapies based on individual patient profiles.

In June 2024, the company partnered with Mika Health have partnered to enhance patient access to psycho-oncology services, biomarker testing, and clinical trials. The partnership was expetected to expand patients’ access to Mika’s Digital Therapeutic for treating oncology-related fatigue, anxiety, and depression. Subsequently, patients using Digital Therapeutic were able opt into Massive Bio’s clinical trial matching and biomarker testing service, while Mika’s Digital Therapy will be available to Massive Bio's cancer patient registry.

Also in June 2024, Massive Bio and Inocras partnered to improve personalized cancer treatment and care.The collaboration involved employing Inocras's whole-genome sequencing (WGS) and bioinformatics expertise with Massive Bio's AI technology for clinical trial matching, which informed cancer patients of prospective clinical trials that align with their genetic profile without the need for additional tests. Massive Bio was also expected to enhance the scope of trial enrollment by reducing screen failures using its predictive analytics.

Funding and financials

In December 2022, the company raised USD 16.5 million in a Series B funding round led by Revo Capital, along with participation from other venture capital firms and individual investors. The raised funds were set aside to expand its capacity to match global demand for its services, along with investing in R&D initiatives.